Mark Silver, MD
Family Medicine · Brookings, ORNPI 1639178114
Payments from drug & device makers
Across 163 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$459
- Johnson & Johnson$377
- GSK$292
- Lilly USA, LLC$283
- AstraZeneca$239
- Otsuka America Pharmaceutical, Inc.$223
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,03897%
- Education$1053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $459 |
| Johnson & Johnson | 17 | $377 |
| GSK | 15 | $292 |
| Lilly USA, LLC | 11 | $283 |
| AstraZeneca | 15 | $239 |
| Otsuka America Pharmaceutical, Inc. | 13 | $223 |
| E.r. Squibb & Sons, L.L.C. | 12 | $213 |
| Novartis | 8 | $138 |
| Astellas Pharma US Inc | 4 | $137 |
| Supernus Pharmaceuticals, Inc. | 9 | $131 |
| Novo Nordisk | 3 | $57 |
| Boehringer Ingelheim | 3 | $55 |
| Sanofi Pasteur Inc. | 2 | $47 |
| Dexcom, Inc. | 2 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $37 |
| Smith+Nephew | 2 | $35 |
| Exact Sciences | 2 | $34 |
| Pfizer | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Bayer | 1 | $23 |
| Amgen | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Alkermes, Inc. | 1 | $16 |
| Organon | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$101
How this compares
$3,143 in reported general payments places this provider in the 90th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 182 | $195,340 |
| OzempicSemaglutide | 58 | $71,253 |
| XareltoRivaroxaban | 42 | $57,230 |
| JardianceEmpagliflozin | 58 | $56,770 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $56,000 |
| CreonLipase/Protease/Amylase | 17 | $55,504 |
| VraylarCariprazine Hcl | 24 | $34,170 |
| FarxigaDapagliflozin Propanediol | 18 | $29,632 |
| MounjaroTirzepatide | 20 | $21,129 |
| Nurtec OdtRimegepant Sulfate | 19 | $20,259 |
| MyrbetriqMirabegron | 16 | $13,479 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 96 | $10,563 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 43 | $9,485 |
| PremarinEstrogens, Conjugated | 26 | $7,950 |
| Gabapentin | 320 | $7,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt, Premarin, Paxlovid | $30 | $226,345241 claims |
| AbbVieCreon, Vraylar, Synthroid | $459 | $93,48798 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta, Arexvy | $292 | $76,064141 claims |
| Novo NordiskOzempic | $57 | $71,25358 claims |
| Johnson & JohnsonXarelto | $377 | $57,23042 claims |
| Boehringer IngelheimJardiance | $55 | $56,77058 claims |
| AstraZenecaFarxiga | $239 | $29,63218 claims |
| Lilly USA, LLCMounjaro | $283 | $21,12920 claims |
| Astellas Pharma US IncMyrbetriq | $137 | $13,47916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Brookings
- John DelgadoAshland$4.3M
- John MickelsonLincoln City$2.1M
- Subramaniam SeetharamanMilwaukie$1.8M
- Eden MillerBend$1.7M
- Maureen MaysPortland$491K
- Thomas TurkRoseburg$434K
- Anil RajaniHood River$325K
- Patricia BuchananEugene$239K
- Keith KlattAstoria$166K
- Stephen NelsonMedford$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.